Leading Covid-19 vaccine developer AstraZeneca agreed on Saturday to buy Boston pharmaceutical firm Alexion for $39 billion.
AstraZeneca agreed to pay for the purchase with a mix of cash and stock, and said it took out a short-term loan of $17.5 billion from Morgan Stanley, J.P. Morgan and Goldman Sachs to help pay for it. Both companies put out a press release Saturday stating their boards of directors unanimously approved the deal.
